N
IMNM icon

Natixis’s Immunome IMNM Stock Holding History

Natixis’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-229,305
Closed -$2.13M – 1137
2025
Q2 		$2.13M Buy
+229,305
New +$1.88M 0.01% 481
2023
Q3 		– Sell
-3,000
Closed -$23.7K – 1060
2023
Q2 		$23.7K Hold
3,000
– – ﹤0.01% 881
2023
Q1 		$15K Sell
3,000
-8,000
-73% -$39.1K ﹤0.01% 878
2022
Q4 		$24.3K Buy
+11,000
New +$44.3K ﹤0.01% 971

Other funds holding IMNM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Natixis's IMNM Position: Q3 2025 in Review

Natixis sold out of Immunome (IMNM) in Q3 2025, closing a stake of 229,305 shares — an estimated $2.13M sold.

Natixis first reported a position in IMNM in Q4 2022 and held it in 4 quarters. The position peaked at $2.13M in Q2 2025. 153 funds tracked by Wall St. Rank hold IMNM as of Q3 2025.

  • Natixis reported no remaining Immunome position as of Q3 2025 after selling out during the quarter.
  • Natixis sold 229,305 Immunome shares in Q3 2025, an estimated $2.13M.
  • Natixis first reported a position in Immunome in Q4 2022 and held it in 4 quarters.
  • Natixis's Immunome position peaked at $2.13M in Q2 2025.
  • 153 funds tracked by Wall St. Rank held Immunome as of Q3 2025.

Based on Natixis's 13F filing for Q3 2025, filed 14 Nov 2025.